Amneal Pharmaceuticals (NASDAQ:AMRX) PT Raised to $12.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price target upped by Truist Financial from $10.00 to $12.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

AMRX has been the topic of several other reports. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an underweight rating to a neutral rating and set a $9.00 target price on the stock in a research report on Friday, September 6th. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an overweight rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of Moderate Buy and a consensus price target of $9.40.

Amneal Pharmaceuticals Trading Up 1.2 %

Shares of AMRX stock opened at $8.65 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.33 and a debt-to-equity ratio of 121.31. The stock has a 50-day simple moving average of $8.16 and a 200 day simple moving average of $7.08. Amneal Pharmaceuticals has a fifty-two week low of $3.36 and a fifty-two week high of $8.94. The stock has a market capitalization of $2.67 billion, a P/E ratio of -15.45 and a beta of 1.18.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The company had revenue of $701.78 million during the quarter, compared to the consensus estimate of $657.43 million. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. On average, sell-side analysts expect that Amneal Pharmaceuticals will post 0.52 earnings per share for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors have recently made changes to their positions in AMRX. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $26,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter worth $42,000. Atlanta Consulting Group Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals during the first quarter worth $61,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals during the second quarter valued at $62,000. Finally, Trexquant Investment LP purchased a new position in Amneal Pharmaceuticals in the fourth quarter valued at about $65,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.